All In Biotech

Free tool

FAERS Monitor: Rhofade

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208552 or its brand name (Rhofade, Oxymetazoline Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

910

Serious

410

45% of reports

Hospitalization

154

Death reported

26

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • application site erythema84
  • drug ineffective64
  • nausea55
  • rosacea54
  • fatigue53
  • application site pain49
  • erythema48
  • pain47
  • pruritus45
  • diarrhoea44
  • condition aggravated39
  • headache39
  • off label use37
  • product dose omission issue37
  • rash30

Reports by year received

View as table
YearReports
20042
20052
20061
20073
20084
20096
20101
20113
20127
201311
20149
201511
201623
201753
201885
201979
202041
202158
2022122
2023132
202491
2025106
202659

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,249 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
rosaceaSignal54271.0208.914,096
application site erythemaSignal8474.360.65,990
application site painSignal4951.539.22,375
erythemaSignal485.44.1169
condition aggravatedSignal393.02.250
product dose omission issueSignal372.92.145
pruritusSignal452.72.048
pain471.81.315
nausea551.61.212
rash301.61.16
diarrhoea441.61.29
fatigue531.61.211
headache391.41.15
drug ineffective641.10.91
off label use371.00.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.